crosscheckdeposited

Células Natural Killer e seu Potencial na Imunoterapia Contra o Câncer

DOI: http://dx.doi.org/10.15602/1983-9480/cmbs.v15n30p17-25

https://www.metodista.br/revistas/revistas-ipa/index.php/EUM/index 

downloadpdf

Bianca P. Bortoncello1, Felipe B. Almeida2 & Alessandra Peres3

 

Resumo: As células Natural Killer (NK) fazem parte do sistema imunológico, mais especificamente da resposta inata, sendo importantes no reconhecimento de células infectadas por patógenos intracelulares e de células tumorais. Sua função efetora se dá através da liberação de substâncias que levam à indução da morte por apoptose da célula alvo. Neste sentido, as células NK são alvo de estudos com o objetivo de utilizar tais células como ferramentas no combate ao câncer através da imunoterapia. Vários estudos têm trazido estratégias promissoras para atingir este objetivo, que vão desde a obtenção das células NK por diferentes fontes e metodologias até a potencialização do seu efeito quando associadas a outros tratamentos. Tais estudos apontam que as células NK, juntamente com outras ferramentas e substâncias, podem ser efetivas no combate ao câncer. O objetivo da presente revisão é apontar os principais aspectos da atualidade relacionados à imunoterapia utilizando as células NK como ferramenta de combate tumoral.

Palavras-chave: imunidade inata, neoplasias, terapia celular

 

Abstract: The Natural Killer (NK) cells are components of the immune system, specifically of the innate response, and are important in the recognition of cells infected by intracellular pathogens and tumor cells. Their effector function occurs through the release of substances that lead to induction of apoptotic death of the target cell. Thus, NK cells are the target of studies focusing on fighting cancer by immunotherapy. Several studies have brought promising strategies to achieve this goal, ranging from the acquisition of NK cells by different sources and methodologies to increase the effect when combined with other treatments. These studies indicate that NK cells, along with other tools and substances can be effective in fighting cancer. The objective of this review is to highlight the current major aspects related to immunotherapy using NK cells as a tool on the combat against tumor development.

Key words: innate immunity, neoplasm, cellular therapy

 

1 Biomédica formada pelo Centro Universitário Metodista – IPA
2 Acadêmico do Curso de Biomedicina da Fundação Universidade Federal de Ciências da Saúde de Porto Alegre
3 Docente do Centro Universitário Metodista – IPA

 

Literatura Citada

CARREGA, Paolo et al. Susceptibility of Human Melanoma Cells to Autologous Natural Killer (NK) Cell Killing: HLA-Related Effector Mechanisms and Role of Unlicensed NK Cells. Plos One, v. 4, n. 12, e8132, dez. 2009. doi

CHO, Duck et al. Cytotoxicity of Activated Natural Killer Cells against Pediatric Solid Tumors. Clinical Cancer Research, v. 16, n. 15, p. 3901-3909, ago. 2010.

CHO, Duck; KIM, Sang-ki; CARSON, William E. NK cell-based immunotherapy for treating cancer: will it be promising? The Korean Journal of Hematology, v. 46, n. 1, p. 3-5, mar. 2011. doi

EL-JURDI, Najla et al. Efficacy of adoptive immunotherapy with donor lymphocyte infusion in relapsed lymphoid malignancies. Immunotherapy, v. 5, n. 5, p. 457-466, mai. 2013.

FERNÁNDEZ, Lucia et al. In vitro natural killer cell immunotherapy for medulloblastoma. Frontiers in Oncology, v. 3, n. 94, abr. 2013.

GARG, Tarun K. et al. Highly activated and expanded natural killer cells for multiple myeloma immunotherapy. Haematologica, v. 97, n. 9, p. 1348-1356, 2012.

GELLER, Melissa A.; MILLER, Jeffrey. S. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy, v. 3, n. 12, p. 1445-1459, 2011. doi

HU, Zhiwei; LI, Jing. Natural killer cells are crucial for the efficacy of Icon (factor VII/human IgG1 Fc) immunotherapy in human tongue cancer. BMC Immunology, v. 11, n. 49, 2010.

JAHN, Tobias et al. An IL12-IL2-Antibody Fusion Protein Targeting Hodgkin’s Lymphoma Cells Potentiates Activation of NK and T cells for an Anti-Tumor Attack. Plos One, v. 7, n. 9, e44482, set. 2012. doi

JHA, Priyanka et al. Monitoring of NK-Cell Immunotherapy using non-invasive Imaging Modalities. Cancer Research, v. 70, n. 15, p. 6109-6113, ago. 2010.

KANG, Lin et al. Characterization and ex vivo expansion of human placenta-derived natural killer cells for cancer immunotherapy. Frontiers in Immunology, v. 4, n. 101, mai. 2013.

LEVY, Estrella Mariel; ROBERTI, María Paula; MORDOH, José. Natural Killer Cells in Human Cancer: From Biological Functions to Clinical Applications. Journal of Biomedicine and Biotechnology, v. 2011, fev. 2011.

NAKAGAWA, Shinichirou et al. New Cancer Immunotherapy Using Autologous Lymphocytes Activated with Trastuzumab. Biological & Pharmaceutical Bulletin, v. 35, n.8, p. 1213-1215, ago. 2012.

PARKHURST, Maria. R. et al. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clinical Cancer Research, v. 17, n. 9, p. 6287-6297, out. 2011.

REINERS, Katrin. S. et al. Rescue of Impaired NK Cell Activity in Hodgkin Lymphoma With Bispecific Antibodies In Vitro and in Patients. Molecular therapy, v. 21, n. 4, p. 895-903, abr. 2013. doi

SALAGIANNI, Maria et al. New insights into the role of NK cells in cancer immunotherapy. OncoImmunology, v. 1, n. 2, p. 205-207, mar.-abr. 2012. doi

SHAHANI, Lokesh; SINGH, Sushma; KHARDORI, Nancy Misri. Immunotherapy in Clinical Medicine: Historical Perspective and Current Status. Medical Clinics of North America, v. 96, p. 421-431, 2012. doi

SHOOK, David R.; CAMPANA, Dario. Natural Killer Cell Engineering for Cellular Therapy of Cancer. Tissue Antigens, v. 78, n. 6, p. 409-415, dez. 2011. doi

SPANHOLTZ, Jan et al. High Log-Scale Expansion of Functional Human Natural Killer Cells from Umbilical Cord Blood CD34-Positive Cells for Adoptive Cancer Immunotherapy. Plos One, v. 5, n. 2, e9221, fev. 2010. doi

SUN, Joseph C.; BEILKE, Joshua N.; LANIER, Lewis L. Adaptive immune features of natural killer cells. Nature, v. 457, n. 29, p. 557-561, fev. 2009.

SUTLU, Tolga.; ALICI, Evren. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. Journal of Internal Medicine, v. 266, p. 154-181, 2009. doi

THIELENS, Ariane; VIVIER, Eric; ROMAGNÉ, François. NK cell MHC class I specific receptors (KIR): from biology to clinical intervention. Current Opinion in Immunology, v. 24, p. 239-245, 2012. doi

VIVIER, Eric et al. Innate or Adaptive Immunity? The Example of Natural Killer Cells. Science, v. 331, n. 44. p. 44-49, jan. 2011.

VIVIER, Eric et al. Targeting natural killer cells and natural killer T cells in cancer. Nature reviews – Immunology, v. 12, p. 239-252, abr. 2012. doi

WALDHAUER, Inja.; STEINLE, Alexander. NK cells and cancer immunosurveillance. Oncogene, v. 27, p. 5932-5943, 2008. doi